Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging
Sufficient expression of somatostatin receptor (SSTR) in well-differentiated neuroendocrine tumors (NETs) is crucial for treatment with somatostatin analogs (SSAs) and peptide receptor radionuclide therapy (PRRT) using radiolabeled SSAs. Impaired prognosis has been described for SSTR-negative NET patients; however, studies comparing matched SSTR-positive and -negative subjects who have not received PRRT are missing. This retrospective analysis of two prospectively maintained NET databases aimed to compare matched metastatic grade 1 or 2 SSTR-positive and -negative NET patients. SSTR-negativity was defined as having insufficient tumor uptake on diagnostic SSTR imaging. Patients that underwent PRRT were excluded. Seventy-seven SSTR-negative and 248 SSTR-positive grade 1-2 NET patients were included. Median overall survival rates were significantly lower for SSTR-negative compared to SSTR-positive NET patients (53 months vs 131 months; P < 0.001). To adjust for possible confounding by age, gender, grade and site of origin, 69 SSTR-negative NET patients were propensity score matched to 69 SSTR-positive NET patients. Group characteristics were similar, with the exception of SSTR-negative patients receiving more often chemotherapy and targeted treatment. The inferior survival outcome of SSTR-negative compared to SSTR-positive NET patients persisted with a median overall survival of 38 months vs 131 months (P = 0.012). This relationship upheld when correcting for the main influencing factors of having a higher grade tumor or receiving surgery in a multivariate Cox regression analysis. In conclusion, we showed that propensity score-matched SSTR-negative NET patients continue to have a worse prognosis compared to SSTR-positive NET patients despite receiving more aggressive treatment. Differences in tumor biology likely underlie this survival deficit.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Endocrine-related cancer - 27(2020), 11 vom: 30. Nov., Seite 615-624 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Refardt, Julie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 28.09.2021 Date Revised 28.09.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1530/ERC-20-0340 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316023019 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316023019 | ||
| 003 | DE-627 | ||
| 005 | 20231225160159.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1530/ERC-20-0340 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1053.xml |
| 035 | |a (DE-627)NLM316023019 | ||
| 035 | |a (NLM)33032265 | ||
| 035 | |a (PII)ERC-20-0340 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Refardt, Julie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.09.2021 | ||
| 500 | |a Date Revised 28.09.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Sufficient expression of somatostatin receptor (SSTR) in well-differentiated neuroendocrine tumors (NETs) is crucial for treatment with somatostatin analogs (SSAs) and peptide receptor radionuclide therapy (PRRT) using radiolabeled SSAs. Impaired prognosis has been described for SSTR-negative NET patients; however, studies comparing matched SSTR-positive and -negative subjects who have not received PRRT are missing. This retrospective analysis of two prospectively maintained NET databases aimed to compare matched metastatic grade 1 or 2 SSTR-positive and -negative NET patients. SSTR-negativity was defined as having insufficient tumor uptake on diagnostic SSTR imaging. Patients that underwent PRRT were excluded. Seventy-seven SSTR-negative and 248 SSTR-positive grade 1-2 NET patients were included. Median overall survival rates were significantly lower for SSTR-negative compared to SSTR-positive NET patients (53 months vs 131 months; P < 0.001). To adjust for possible confounding by age, gender, grade and site of origin, 69 SSTR-negative NET patients were propensity score matched to 69 SSTR-positive NET patients. Group characteristics were similar, with the exception of SSTR-negative patients receiving more often chemotherapy and targeted treatment. The inferior survival outcome of SSTR-negative compared to SSTR-positive NET patients persisted with a median overall survival of 38 months vs 131 months (P = 0.012). This relationship upheld when correcting for the main influencing factors of having a higher grade tumor or receiving surgery in a multivariate Cox regression analysis. In conclusion, we showed that propensity score-matched SSTR-negative NET patients continue to have a worse prognosis compared to SSTR-positive NET patients despite receiving more aggressive treatment. Differences in tumor biology likely underlie this survival deficit | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a neuroendocrine tumor | |
| 650 | 4 | |a propensity score | |
| 650 | 4 | |a somatostatin receptor | |
| 650 | 4 | |a survival | |
| 650 | 7 | |a Receptors, Somatostatin |2 NLM | |
| 700 | 1 | |a Zandee, Wouter T |e verfasserin |4 aut | |
| 700 | 1 | |a Brabander, Tessa |e verfasserin |4 aut | |
| 700 | 1 | |a Feelders, Richard A |e verfasserin |4 aut | |
| 700 | 1 | |a Franssen, Gaston J H |e verfasserin |4 aut | |
| 700 | 1 | |a Hofland, Leo J |e verfasserin |4 aut | |
| 700 | 1 | |a Christ, Emanuel |e verfasserin |4 aut | |
| 700 | 1 | |a de Herder, Wouter W |e verfasserin |4 aut | |
| 700 | 1 | |a Hofland, Johannes |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Endocrine-related cancer |d 1997 |g 27(2020), 11 vom: 30. Nov., Seite 615-624 |w (DE-627)NLM093797834 |x 1479-6821 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2020 |g number:11 |g day:30 |g month:11 |g pages:615-624 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1530/ERC-20-0340 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2020 |e 11 |b 30 |c 11 |h 615-624 | ||